Argenx announced that the FDA has extended the review of the biologics license application, or BLA, for subcutaneous, or SC, efgartigimod for the treatment of adult patients with generalized myasthenia gravis, or gMG, to June 20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- Argenx price target raised to $458 from $441 at Cowen
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- Argenx reports preliminary Q4 Vyvgart revenue $175M
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline